AU Patent

AU2018279834A1 — Liquid dosage forms to treat cancer

Assigned to Exelixis Inc · Expires 2020-01-16 · 6y expired

What this patent protects

This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

USPTO Abstract

This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018279834A1
Jurisdiction
AU
Classification
—
Expires
2020-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.